imatinib mesylate has been researched along with Digestive System Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiya, M; Inoue, M; Kohgo, Y; Muto, M; Okada, T; Yabuki, H | 1 |
| Al-Batran, SE; Atmaca, A; Ehninger, G; Hosius, C; Jäger, E; Pauligk, C; Schleyer, E | 1 |
| Chang, HM; Kang, YK; Kim, BS; Kim, HC; Kim, KH; Kim, TW; Lee, JL; Ryu, MH; Sym, SJ; Yook, JH | 1 |
2 trial(s) available for imatinib mesylate and Digestive System Neoplasms
| Article | Year |
|---|---|
Imatinib mesylate for targeting the platelet-derived growth factor beta receptor in combination with fluorouracil and leucovorin in patients with refractory pancreatic, bile duct, colorectal, or gastric cancer--a dose-escalation Phase I trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Imatinib Mesylate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines | 2007 |
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Premedication; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Rate | 2008 |
1 other study(ies) available for imatinib mesylate and Digestive System Neoplasms
| Article | Year |
|---|---|
An invasive extragastrointestinal stromal tumor curably resected following imatinib treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Biopsy, Fine-Needle; Chemotherapy, Adjuvant; Digestive System Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Magnetic Resonance Imaging; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasms, Multiple Primary; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |